HER2 inhibitors have significantly improved the prognosis for patients with HER2-positive cancers. They have been shown to reduce tumor size, delay disease progression, and improve overall survival rates. For example, the introduction of trastuzumab has been a game-changer in the management of HER2-positive breast cancer, transforming it from one of the most aggressive subtypes to one that is very treatable.
